Evidence map›Paper›PMID 38032112›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Fluorescence-Quenching Lateral Flow Immunoassay for "Turn-On" and Sensitive Detection of Anti-SARS-Cov-2 Neutralizing Antibodies in Human Serum.

Lun Bian, Qiangqiang Fu, Zhuoheng Gan, Ze Wu, Yuchen Song, Yufeng Xiong, Fang Hu, Lei Zheng

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. A Two-Stage Cascading Amplification Strategy Based on ZnAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lun BianBiomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China.ORCID 0000-0001-9950-760X
Qiangqiang FuDepartment of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Zhuoheng GanBiomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China.
Ze WuDepartment of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Yuchen SongBiomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China.
Yufeng XiongDepartment of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Fang HuBiomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China.
Lei ZhengDepartment of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.ORCID 0000-0003-2576-8780
Nanfang Hospital · CNSouthern Medical University · CNZhujiang Hospital · CN

Funding

Guangzhou Municipal Science and Technology Bureau 202201011254
6 · The paper itself

Abstract

The titer of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies (NAbs) in the human body is an essential reference for evaluating the acquired protective immunity and resistance to SARS-CoV-2 infection. In this study, a fluorescence-quenching lateral flow immunoassay (FQ-LFIA) is established for quantitative detection of anti-SARS-CoV-2 NAbs in the sera of individuals who are vaccinated or infected within 10 min. The ultrabright aggregation-induced emission properties encapsulated in nanoparticles, AIE

Indexed as

COVID-19Metal NanoparticlesAntibodies, NeutralizingAntibodies, ViralGoldHumansImmunoassaySARS-CoV-2Antibodies, NeutralizingAntibodies, ViralGoldaggregation-induced emissionfluorescence-quenchinglateral flow immunoassayneutralizing antibodiesSARS-CoV-2

Identifiers

PMID38032112
PMCPMC10811470
OpenAlexW4389180173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.